Imuran Mitis (Azathioprine)

Azathioprine is converted to 6‑mercaptopurine inside cells, where it blocks purine synthesis. This limits DNA replication in rapidly dividing lymphocytes, reducing their proliferation and dampening the immune response that drives inflammation and graft rejection.

The appropriate dose of Imuran Mitis is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and laboratory monitoring results. Patients should follow the exact regimen provided by their healthcare professional.

Azathioprine is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should generally be avoided during pregnancy unless the potential benefit justifies the risk. Limited data exist for breastfeeding; the decision should be made with a physician’s guidance.

To request Imuran Mitis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both azathioprine and mycophenolate mofetil are antimetabolite immunosuppressants, but they inhibit different enzymes in the purine pathway. Azathioprine is often used where mycophenolate is contraindicated or not tolerated, and each drug has a distinct side‑effect profile and monitoring requirements.

Imuran Mitis should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keeping the tablet in a dry, cool place helps maintain its potency throughout its shelf life.

Imuran Mitis is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact dosing schedule—once daily, twice daily, or as otherwise directed—must follow the prescribing clinician’s instructions.

Serious risks include bone marrow aplasia leading to severe pancytopenia, life‑threatening infections due to immunosuppression, hepatotoxicity that can progress to liver failure, and an increased long‑term risk of certain malignancies. Prompt reporting of symptoms such as fever, unexplained bruising or jaundice is essential.

Imuran Mitis is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites, those with active severe infections, pregnant women unless absolutely necessary, and individuals with severe hepatic or bone‑marrow impairment. A thorough medical assessment is required before initiation.